B-cell Lymphoma Unclassifiable with Features Intermediate Between Dlbcl and Classic Hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for B-cell Lymphoma Unclassifiable with Features Intermediate Between Dlbcl and Classic Hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-02-01Clinical Trial Update: Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. [Phase 1]
Phase 1 study of pembrolizumab plus vorinostat in relapsed or refractory B-cell lymphomas and classic Hodgkin lymphoma; results posted in Fe…